Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,821 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.
Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, Cui Y, Qu X, Chang T, Yu S, Cheng Y, Zhou Y, Chen J, Ren Q, Wang W, Deng Q, Wang Z, Yang H. Liu G, et al. Among authors: qu x. Expert Opin Biol Ther. 2022 Feb;22(2):187-195. doi: 10.1080/14712598.2021.1988567. Epub 2021 Oct 18. Expert Opin Biol Ther. 2022. PMID: 34607519 Clinical Trial.
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects.
Xu Z, Wang Y, Liu G, Chen J, Wang W, Cheng Y, Ren Q, Cui Y, Yang W, Liu Z, Chen X, Xue J, Chang T, Qu X, Yu S, Zhou Y, Xu K, Su Z, Deng Q, Zhao Y, Yang H. Xu Z, et al. Among authors: qu x. Expert Opin Investig Drugs. 2022 Jul;31(7):737-746. doi: 10.1080/13543784.2022.2067528. Epub 2022 Apr 19. Expert Opin Investig Drugs. 2022. PMID: 35427205 Clinical Trial.
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
Xu Z, Wang Y, Liu Z, Zhang R, Zhou Y, Yu J, Lan J, Liang W, Liu G, Qu X, Chen J, Su Z, Yu S, Cheng Y, Wang W, Ren Q, Deng Q, Zhao Y, Yang H. Xu Z, et al. Among authors: qu x. Int Immunopharmacol. 2022 Aug;109:108780. doi: 10.1016/j.intimp.2022.108780. Epub 2022 Apr 20. Int Immunopharmacol. 2022. PMID: 35461158 Clinical Trial.
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects.
Liu G, Xue J, Wang Y, Liu Z, Li X, Qu D, Su Z, Xu K, Qu X, Qu Z, Sun L, Cao M, Wang Y, Chen X, Yu J, Liu L, Deng Q, Zhao Y, Zhang L, Yang H. Liu G, et al. Among authors: qu x, qu z, qu d. J Cancer Res Clin Oncol. 2023 Jun;149(6):2585-2593. doi: 10.1007/s00432-022-04148-1. Epub 2022 Jun 30. J Cancer Res Clin Oncol. 2023. PMID: 35771264 Clinical Trial.
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
Xu Z, Liu Z, Wang Y, Xue J, Chang T, Cui Y, Cheng Y, Liu G, Wang W, Zhou Y, Yu S, Ren Q, Yang W, Qu X, Chen J, Chen X, Deng Q, Yang H, Wang X. Xu Z, et al. Among authors: qu x. Expert Rev Clin Pharmacol. 2023 Apr;16(4):363-370. doi: 10.1080/17512433.2023.2188192. Epub 2023 Mar 8. Expert Rev Clin Pharmacol. 2023. PMID: 36883362 Clinical Trial.
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.
Liu Z, Xue J, Deng Q, Wang Y, Zhang L, Liu L, Xiao N, Chang T, Cui Y, Cheng Y, Liu G, Wang W, Zhou Y, Yang W, Qu X, Chen J, Zhao Y, Wang Z, Yang H. Liu Z, et al. Among authors: qu x. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):7051-7060. doi: 10.1007/s00210-024-03055-1. Epub 2024 Apr 21. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38643450 Clinical Trial.
5,821 results